nach oben

01.11.2019 | Food Allergy (E Kim, Section Editor) | Ausgabe 11/2019

Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies

Zeitschrift:: Current Allergy and Asthma Reports > Ausgabe 11/2019

Autoren:: Mary Grace Baker, Julie Wang

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

This article is part of the Topical Collection on Food Allergy

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose of Review

Over the last decade, there has been a spark in innovation in the development of therapies for food allergy. Herein, we describe the background and recent advances for food-specific immunotherapies including epicutaneous (EPIT), sublingual (SLIT), and subcutaneous (SCIT).

Recent Findings

Studies have progressed most quickly for the treatment of peanut allergy. Data from the phase 3 EPIT trial add to the accumulating evidence that this will be a viable therapy for peanut allergy. Studies for SLIT and SCIT remain in earlier phases with promising results.

Summary

This is an exciting era for the treatment of food allergy. Multiple therapies are under investigation, each with their own potential advantages. Specific strengths and limitations of each of these therapies may provide an opportunity to personalize the choice of therapy for individual patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

★ PREMIUM-INHALT

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt gratis testen * Jetzt kaufen

Sie können e.Med Interdisziplinär 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention and management. J Allergy Clin Immunol. 2018;141(1):41–58. https://doi.org/10.1016/j.jaci.2017.11.003. CrossRefPubMed

National Academies of Sciences E, Medicine, Health, Medicine D, Food, Nutrition B, et al. In: Oria MP, Stallings VA, editors. Finding a path to safety in food allergy: assessment of the Global Burden, Causes, Prevention, Management, and Public Policy. Washington (DC): National Academies Press (US); 2016.

Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol. 2011;127(3):668–76.e1–2. https://doi.org/10.1016/j.jaci.2011.01.039. CrossRefPubMed

King RM, Knibb RC, Hourihane JOB. Impact of peanut allergy on quality of life, stress and anxiety in the family. Allergy. 2009;64(3):461–8. https://doi.org/10.1111/j.1398-9995.2008.01843.x. CrossRefPubMed

Flokstra-de Blok BM, Dubois AE, Vlieg-Boerstra BJ, Oude Elberink JN, Raat H, DunnGalvin A, et al. Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy. 2010;65(2):238–44. https://doi.org/10.1111/j.1398-9995.2009.02121.x. CrossRefPubMed

Simonte SJ, Ma S, Mofidi S, Sicherer SH. Relevance of casual contact with peanut butter in children with peanut allergy. J Allergy Clin Immunol. 2003;112(1):180–2. https://doi.org/10.1067/mai.2003.1486. CrossRefPubMed

Weinberger T, Annunziato R, Riklin E, Shemesh E, Sicherer SH. A randomized controlled trial to reduce food allergy anxiety about casual exposure by holding the allergen: TOUCH study. J Allergy Clin Immunol Pract. 2019;7(6):2039–42.e14. https://doi.org/10.1016/j.jaip.2019.01.018. CrossRefPubMed

Wang J, Bingemann T, Russell AF, Young MC, Sicherer SH. The allergist’s role in anaphylaxis and food allergy management in the school and childcare setting. J Allergy Clin Immunol Pract. 2018;6(2):427–35. https://doi.org/10.1016/j.jaip.2017.11.022. CrossRefPubMed

Lieberman JA, Weiss C, Furlong TJ, Sicherer M, Sicherer SH. Bullying among pediatric patients with food allergy. Ann Allergy Asthma Immunol. 2010;105(4):282–6. https://doi.org/10.1016/j.anai.2010.07.011. CrossRefPubMed

10.

• Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy. J Allergy Clin Immunol Pract. 2018;6(2):457–65.e4. https://doi.org/10.1016/j.jaip.2017.05.006 Model of US food consumption data and estimated peanut contamination suggesting protective peanut threshold. CrossRefPubMed

11.

Remington BC, Krone T, Koppelman SJ. Quantitative risk reduction through peanut immunotherapy: safety benefits of an increased threshold in Europe. Pediatr Allergy Immunol. 2018;29(7):762–72. https://doi.org/10.1111/pai.12961. CrossRefPubMed

12.

Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137(4):1258–61.e10. https://doi.org/10.1016/j.jaci.2016.01.008. CrossRefPubMed

13.

• Jones SM, Sicherer SH, Burks AW, Leung DYM, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–52.e9. https://doi.org/10.1016/j.jaci.2016.08.017 Phase 2b study of peanut patch. CrossRefPubMed

14.

• Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809. https://doi.org/10.1001/jama.2017.16591 Phase 2b study of peanut patch. CrossRefPubMedPubMedCentral

15.

•• Fleischer DM, Greenhawt M, Sussman G, Begin P, Nowak-Wegrzyn A, Petroni D, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial. JAMA. 2019. https://doi.org/10.1001/jama.2019.1113 Phase 3 study of peanut patch. CrossRef

16.

Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640–6.e1. https://doi.org/10.1016/j.jaci.2010.12.1083. CrossRefPubMedPubMedCentral

17.

Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27.e1–7. https://doi.org/10.1016/j.jaci.2012.11.011. CrossRefPubMed

18.

Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol. 2013;132(2):476–8.e2. https://doi.org/10.1016/j.jaci.2013.02.017. CrossRefPubMedPubMedCentral

19.

Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82.e1–6. https://doi.org/10.1016/j.jaci.2014.11.005. CrossRefPubMed

20.

• Bindslev-Jensen C, de Kam P-J, van Twuijver E, Boot DB, El Galta R, Mose AP, et al. SCIT-treatment with a chemically modified, aluminum hydroxide adsorbed peanut extract (HAL-MPE1) was generally safe and well tolerated and showed immunological changes in peanut allergic patients. J Allergy Clin Immunol. 2017;139(2, Supplement):AB191. https://doi.org/10.1016/j.jaci.2016.12.623 Phase 1 safety study of recombinant peanut vaccine HAL-MPE1. CrossRef

21.

Li X-M, Song Y, Su Y, Heiland T, Sampson HA. Immunization with ARA h1,2,3-LAMP-Vax peanut vaccine blocked IgE mediated-anaphylaxis in a peanut allergic murine model. J Allergy Clin Immunol. 2015;135(2):AB167. https://doi.org/10.1016/j.jaci.2014.12.1482. CrossRef

22.

Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125(5):1165–7. https://doi.org/10.1016/j.jaci.2010.02.029. CrossRefPubMed

23.

Rutault K, Agbotounou W, Peillon A, Thébault C, Vincent F, Martin L, et al. Safety of Viaskin milk epicutaneous immunotherapy (EPIT) in IgE-mediated cow’s milk allergy (CMA) in children (MILES study). J Allergy Clin Immunol. 2016;137(2):AB132. https://doi.org/10.1016/j.jaci.2015.12.566. CrossRef

24.

de Boissieu D, Dupont C. Sublingual immunotherapy for cow’s milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238–9. https://doi.org/10.1111/j.1398-9995.2006.01196.x. CrossRefPubMed

25.

Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55, 55.e1–5. https://doi.org/10.1016/j.jaci.2011.10.023. CrossRefPubMed

26.

Vallery-Radot P, Hangenau J. Asthme d’origine equine. Essai de desensibilisation par des cutireactions repetees. Bull Soc Med Hop Paris. 1921;45:1251–60.

27.

Wang J, Sampson HA. Safety and efficacy of epicutaneous immunotherapy for food allergy. Pediatr Allergy Immunol. 2018;29(4):341–9. https://doi.org/10.1111/pai.12869. CrossRefPubMed

28.

Wood LC, Jackson SM, Elias PM, Grunfeld C, Feingold KR. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest. 1992;90(2):482–7. https://doi.org/10.1172/jci115884. CrossRefPubMedPubMedCentral

29.

Brough HA, Liu AH, Sicherer S, Makinson K, Douiri A, Brown SJ, et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol. 2015;135(1):164–70. https://doi.org/10.1016/j.jaci.2014.10.007. CrossRefPubMedPubMedCentral

30.

Venkataraman D, Soto-Ramirez N, Kurukulaaratchy RJ, Holloway JW, Karmaus W, Ewart SL, et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol. 2014;134(4):876–82.e4. https://doi.org/10.1016/j.jaci.2014.07.033. CrossRefPubMedPubMedCentral

31.

Mondoulet L, Dioszeghy V, Puteaux E, Ligouis M, Dhelft V, Letourneur F, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy. 2012;2(1):22. https://doi.org/10.1186/2045-7022-2-22. CrossRefPubMedPubMedCentral

32.

Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40(4):659–67. https://doi.org/10.1111/j.1365-2222.2009.03430.x. CrossRefPubMed

33.

Dioszeghy V, Mondoulet L, Laoubi L, Dhelft V, Plaquet C, Bouzereau A, et al. Antigen uptake by Langerhans cells is required for the induction of regulatory T cells and the acquisition of tolerance during epicutaneous immunotherapy in OVA-sensitized mice. Front Immunol. 2018;9:1951. https://doi.org/10.3389/fimmu.2018.01951. CrossRefPubMedPubMedCentral

34.

Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol (Baltimore, Md : 1950). 2011;186(10):5629–37. https://doi.org/10.4049/jimmunol.1003134. CrossRef

35.

Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP(+) regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139(1):189–201.e4. https://doi.org/10.1016/j.jaci.2016.03.057. CrossRefPubMed

36.

Dioszeghy V, Mondoulet L, Puteaux E, Dhelft V, Ligouis M, Plaquet C, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cell Mol Immunol. 2017;14(9):770–82. https://doi.org/10.1038/cmi.2016.14. CrossRefPubMed

37.

Mondoulet L, Dioszeghy V, Vanoirbeek JA, Nemery B, Dupont C, Benhamou PH. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol. 2011;154(4):299–309. https://doi.org/10.1159/000321822. CrossRefPubMed

38.

Remington B, Krone T, Koppelman S. Quantitative risk reduction through epicutaneous immunotherapy (EPIT): results from the PEPITES phase III trial. Ann Allergy Asthma Immunol. 2018;121(5):S11. https://doi.org/10.1016/j.anai.2018.09.032. CrossRef

39.

Mondoulet L, Dioszeghy V, Larcher T, Ligouis M, Dhelft V, Puteaux E, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One. 2012;7(2):e31967-e. https://doi.org/10.1371/journal.pone.0031967. CrossRef

40.

Mondoulet L, Kalach N, Dhelft V, Larcher T, Delayre-Orthez C, Benhamou PH, et al. Treatment of gastric eosinophilia by epicutaneous immunotherapy in piglets sensitized to peanuts. Clin Exp Allergy. 2017;47(12):1640–7. https://doi.org/10.1111/cea.13037. CrossRefPubMed

41.

Spergel JM, Elci OU, Muir AB, Liacouras CA, Wilkins BJ, Burke D, et al. Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.05.014.

42.

Cox LS. Sublingual immunotherapy: historical perspective and practical guidance. J Allergy Clin Immunol Pract. 2017;5(1):63–5. https://doi.org/10.1016/j.jaip.2016.11.016. CrossRefPubMed

43.

Mahler V, Esch RE, Kleine-Tebbe J, Lavery WJ, Plunkett G, Vieths S, et al. Understanding differences in allergen immunotherapy products and practices in North America and Europe. J Allergy Clin Immunol. 2019;143(3):813–28. https://doi.org/10.1016/j.jaci.2019.01.024. CrossRefPubMed

44.

Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep. 2014;14(11):473. https://doi.org/10.1007/s11882-014-0473-1. CrossRefPubMed

45.

Marcucci F, Incorvaia C, Sensi L, Di Cara G, Cadario G, Cavaliere A, et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immunopathol Pharmacol. 2008;21(3):609–13. https://doi.org/10.1177/039463200802100314. CrossRefPubMed

46.

Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2. https://doi.org/10.1186/2045-7022-2-2. CrossRefPubMedPubMedCentral

47.

Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy. 2006;61(Suppl 81):11–4. https://doi.org/10.1111/j.1398-9995.2006.01159.x. CrossRefPubMed

48.

Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–9. https://doi.org/10.1016/j.jaci.2005.08.027. CrossRefPubMed

49.

Cafone J, Capucilli P, Hill DA, Spergel JM. Eosinophilic esophagitis during sublingual and oral allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2019. https://doi.org/10.1097/aci.0000000000000537. CrossRef

50.

Lawrence MG, Steinke JW, Borish L. Basic science for the clinician: mechanisms of sublingual and subcutaneous immunotherapy. Ann Allergy Asthma Immunol. 2016;117(2):138–42. https://doi.org/10.1016/j.anai.2016.06.027. CrossRefPubMedPubMedCentral

51.

Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55. https://doi.org/10.1016/j.jaci.2010.09.034. CrossRefPubMed

52.

Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90(2):256–62. CrossRef

53.

Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt 1):744–51. CrossRef

54.

Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68(6):803–8. https://doi.org/10.1111/all.12158. CrossRefPubMedPubMedCentral

55.

Feuille E, Nowak-Wegrzyn A. Allergen-specific immunotherapies for food allergy. Allergy, Asthma Immunol Res. 2018;10(3):189–206. https://doi.org/10.4168/aair.2018.10.3.189. CrossRef

56.

Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192(9):1213–22. https://doi.org/10.1084/jem.192.9.1213. CrossRefPubMedPubMedCentral

57.

van der Kleij HPM, Warmenhoven HJM, van Ree R, Versteeg SA, Pieters RHH, Dreskin SC, et al. Chemically modified peanut extract shows increased safety while maintaining immunogenicity. Allergy. 2018. https://doi.org/10.1111/all.13687. CrossRef

58.

Palmer GW, Dibbern DA Jr, Burks AW, Bannon GA, Bock SA, Porterfield HS, et al. Comparative potency of Ara h 1 and Ara h 2 in immunochemical and functional assays of allergenicity. Clin Immunol (Orlando, Fla). 2005;115(3):302–12. https://doi.org/10.1016/j.clim.2005.02.011. CrossRef

59.

Porterfield HS, Murray KS, Schlichting DG, Chen X, Hansen KC, Duncan MW, et al. Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. Clin Exp Allergy. 2009;39(7):1099–108. https://doi.org/10.1111/j.1365-2222.2009.03273.x. CrossRefPubMedPubMedCentral

60.

Kulis M, Chen X, Lew J, Wang Q, Patel OP, Zhuang Y, et al. The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice. Clin Exp Allergy. 2012;42(2):326–36. https://doi.org/10.1111/j.1365-2222.2011.03934.x. CrossRefPubMedPubMedCentral

61.

Chen X, Wang Q, El-Mezayen R, Zhuang Y, Dreskin SC. Ara h 2 and Ara h 6 have similar allergenic activity and are substantially redundant. Int Arch Allergy Immunol. 2013;160(3):251–8. https://doi.org/10.1159/000341642. CrossRefPubMed

62.

Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy. 2004;34(9):1373–8. https://doi.org/10.1111/j.1365-2222.2004.02052.x. CrossRefPubMed

63.

Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365):152–4. https://doi.org/10.1038/356152a0. CrossRefPubMed

64.

Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745–9. https://doi.org/10.1126/science.8456302. CrossRefPubMed

65.

Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62–84. https://doi.org/10.1111/j.1600-065X.2010.00980.x. CrossRefPubMed

66.

Su Y, Connolly M, Marketon A, Heiland T. CryJ-LAMP DNA vaccines for Japanese red cedar allergy induce robust Th1-type immune responses in murine model. J Immunol Res. 2016;2016:4857869. https://doi.org/10.1155/2016/4857869. CrossRefPubMedPubMedCentral

67.

Su Y, Romeu-Bonilla E, Anagnostou A, Fitz-Patrick D, Hearl W, Heiland T. Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: a phase I study. Hum Vaccin Immunother. 2017;13(12):2804–13. https://doi.org/10.1080/21645515.2017.1329070. CrossRefPubMedPubMedCentral

68.

Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;121(3):293–305. https://doi.org/10.1016/j.anai.2018.07.014. CrossRefPubMed

69.

Johnson-Weaver BT, Staats HF, Burks AW, Kulis MD. Adjuvanted immunotherapy approaches for peanut allergy. Front Immunol. 2018;9:2156. https://doi.org/10.3389/fimmu.2018.02156. CrossRefPubMedPubMedCentral

70.

Kramer MF, Heath MD. Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective. Vaccine. 2014;32(33):4140–8. https://doi.org/10.1016/j.vaccine.2014.05.063. CrossRefPubMed

71.

Jensen-Jarolim E. Aluminium in allergies and allergen immunotherapy. World Allergy Organ J. 2015;8(1):7. https://doi.org/10.1186/s40413-015-0060-5. CrossRefPubMedPubMedCentral

72.

Hong S-J, Michael JG, Fehringer A, Leung DYM. Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes. J Allergy Clin Immunol. 1999;104(2):473–7. https://doi.org/10.1016/S0091-6749(99)70396-9. CrossRefPubMed

73.

Li S, Li X, Burks A, Bannon G, Sampson H. Modulation of peanut allergy by peptide-based immunotherapy. J Allergy Clin Immunol. 2001;107(2).

74.

Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O’Hehir RE. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol. 2011;127(3):608–15.e5. https://doi.org/10.1016/j.jaci.2010.09.027. CrossRefPubMed

75.

Kulis M, MacQueen I, Li Y, Guo R, Zhong X-P, Burks AW. Pepsinized cashew proteins are hypoallergenic and immunogenic and provide effective immunotherapy in mice with cashew allergy. J Allergy Clin Immunol. 2012;130(3):716–23. https://doi.org/10.1016/j.jaci.2012.05.044. CrossRefPubMed

76.

Shen W, Marketon A, Su Y, Macauley J, Heiland T. Development of LAMP-based vaccine for cashew allergy immunotherapy. J Immunol. 2016;196(1 Supplement):215.8–.8.

77.

Greenhawt M, Marsh R, Gilbert H, Sicherer S, DunnGalvin A, Matlock D. Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies. Ann Allergy Asthma Immunol. 2018;121(5):575–9. https://doi.org/10.1016/j.anai.2018.06.018. CrossRefPubMed

Titel: Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies
Autoren:: Mary Grace Baker
Julie Wang
Publikationsdatum: 01.11.2019
DOI: https://doi.org/10.1007/s11882-019-0885-z
Verlag: Springer US
Zeitschrift: Current Allergy and Asthma Reports
Ausgabe 11/2019
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315

Neu im Fachgebiet HNO

Vergleich

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies

Publisher’s Note

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

Die COVID-19-Impfquoten – in Deutschland und der Welt

Schützt Kiffen vor Oropharyngealtumoren?

Tipps zur Sterilisation von N95-Masken

Ärzte fühlen sich auf Corona-Impfgespräche gut vorbereitet

Newsletter